Drug Metabolism Reviews最新文献_第4页

Advances in drug resistance of osteosarcoma caused by pregnane X receptor. 孕烷 X 受体导致骨肉瘤耐药性的研究进展。

IF 3.8 2区医学

Drug Metabolism Reviews Pub Date : 2024-11-01 Epub Date: 2024-06-13 DOI: 10.1080/03602532.2024.2366948

Kunhong Mao, Can Liu, Zhongwen Tang, Zhouzhou Rao, Jie Wen

引用次数: 0

The role and current research status of resveratrol in the treatment of osteoarthritis and its mechanisms: a narrative review. 白藜芦醇在骨关节炎治疗中的作用和研究现状及其机制：综述。

IF 3.8 2区医学

Drug Metabolism Reviews Pub Date : 2024-11-01 Epub Date: 2024-10-08 DOI: 10.1080/03602532.2024.2402751

Xiongfei Zou, Hongjun Xu, Wenwei Qian

{"title":"The role and current research status of resveratrol in the treatment of osteoarthritis and its mechanisms: a narrative review.","authors":"Xiongfei Zou, Hongjun Xu, Wenwei Qian","doi":"10.1080/03602532.2024.2402751","DOIUrl":"10.1080/03602532.2024.2402751","url":null,"abstract":"Osteoarthritis (OA) is a chronic degenerative disease caused by various factors such as aging, obesity, trauma, and genetics. It is a challenging condition faced by orthopedic doctors in clinical practice and places a heavy burden on patients and their families. Currently, the treatment of OA primarily focuses on symptomatic relief and lacks ideal therapeutic methods. Resveratrol is a natural polyphenolic compound with anti-inflammatory and antioxidant properties, and in recent years, it has gained attention as a candidate drug for OA treatment. This article provides an overview of the research status on the role and mechanisms of resveratrol in treating OA. It has been found that resveratrol can prevent the development of OA by inhibiting inflammatory responses, protecting chondrocytes, maintaining cartilage homeostasis, promoting autophagy, and has shown certain therapeutic effects. This process may be related to the regulation of signaling pathways such as nuclear factor-kappa B (NF-κB), Toll-like receptor 4 (TLR4), and silent information regulator 1 (SIRT1). We summarize the current molecular mechanisms of resveratrol in treating OA, hoping to provide a reference for further research and application of resveratrol in OA treatment.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"399-412"},"PeriodicalIF":3.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ocular drug-metabolizing enzymes: focus on esterases. 眼部药物代谢酶：聚焦酯酶。

IF 3.8 2区医学

Drug Metabolism Reviews Pub Date : 2024-08-01 Epub Date: 2024-06-19 DOI: 10.1080/03602532.2024.2368247

Anam Hammid, Paavo Honkakoski

引用次数: 0

Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs). 表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKIs）的肝毒性。

IF 3.8 2区医学

Drug Metabolism Reviews Pub Date : 2024-08-01 Epub Date: 2024-08-09 DOI: 10.1080/03602532.2024.2388203

Lulin Zhu, Xinxin Yang, Shanshan Wu, Rong Dong, Youyou Yan, Nengming Lin, Bo Zhang, Biqin Tan

{"title":"Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs).","authors":"Lulin Zhu, Xinxin Yang, Shanshan Wu, Rong Dong, Youyou Yan, Nengming Lin, Bo Zhang, Biqin Tan","doi":"10.1080/03602532.2024.2388203","DOIUrl":"10.1080/03602532.2024.2388203","url":null,"abstract":"Drug-induced liver injury (DILI) is one of the most frequently adverse reactions in clinical drug use, usually caused by drugs or herbal compounds. Compared with other populations, cancer patients are more prone to abnormal liver function due to primary or secondary liver malignant tumor, radiation-induced liver injury and other reasons, making potential adverse reactions from liver damage caused by anticancer drugs of particular concernduring clinical treatment process. In recent years, the application of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has changed the treatment status of a series of solid malignant tumors. Unfortunately, the increasing incidence of hepatotoxicitylimits the clinical application of EGFR-TKIs. The mechanisms of liver injury caused by EGFR-TKIs were complex. Despite more than a decade of research, other than direct damage to hepatocytes caused by inhibition of cellular DNA synthesis and resulting in hepatocyte necrosis, the rest of the specific mechanisms remain unclear, and few effective solutions are available. This review focuses on the clinical feature, incidence rates and the recent advances on the discovery of mechanism of hepatotoxicity in EGFR-TKIs, as well as rechallenge and therapeutic strategies underlying hepatotoxicity of EGFR-TKIs.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"302-317"},"PeriodicalIF":3.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bioactivation and reactivity research advances - 2023 year in review. 生物活化和反应研究进展--2023 年回顾。

IF 3.8 2区医学

Drug Metabolism Reviews Pub Date : 2024-08-01 Epub Date: 2024-07-17 DOI: 10.1080/03602532.2024.2376023

Shuai Wang, Upendra A Argikar, Maria Chatzopoulou, Sungjoon Cho, Rachel D Crouch, Deepika Dhaware, Ting-Jia Gu, Carley J S Heck, Kevin M Johnson, Amit S Kalgutkar, Joyce Liu, Bin Ma, Grover P Miller, Jessica A Rowley, Herana Kamal Seneviratne, Donglu Zhang, S Cyrus Khojasteh

{"title":"Bioactivation and reactivity research advances - 2023 year in review.","authors":"Shuai Wang, Upendra A Argikar, Maria Chatzopoulou, Sungjoon Cho, Rachel D Crouch, Deepika Dhaware, Ting-Jia Gu, Carley J S Heck, Kevin M Johnson, Amit S Kalgutkar, Joyce Liu, Bin Ma, Grover P Miller, Jessica A Rowley, Herana Kamal Seneviratne, Donglu Zhang, S Cyrus Khojasteh","doi":"10.1080/03602532.2024.2376023","DOIUrl":"10.1080/03602532.2024.2376023","url":null,"abstract":"Advances in the field of bioactivation have significantly contributed to our understanding and prediction of drug-induced liver injury (DILI). It has been established that many adverse drug reactions, including DILI, are associated with the formation and reactivity of metabolites. Modern methods allow us to detect and characterize these reactive metabolites in earlier stages of drug development, which helps anticipate and circumvent the potential for DILI. Improved in silico models and experimental techniques that better reflect in vivo environments are enhancing predictive capabilities for DILI risk. Further, studies on the mechanisms of bioactivation, including enzyme interactions and the role of individual genetic differences, have provided valuable insights for drug optimizations. Cumulatively, this progress is continually refining our approaches to drug safety evaluation and personalized medicine.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"247-284"},"PeriodicalIF":3.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanisms of intestinal pharmacokinetic natural product-drug interactions. 肠道药代动力学天然产品与药物相互作用的机制。

IF 3.8 2区医学

Drug Metabolism Reviews Pub Date : 2024-08-01 Epub Date: 2024-08-12 DOI: 10.1080/03602532.2024.2386597

Victoria O Oyanna, John D Clarke

{"title":"Mechanisms of intestinal pharmacokinetic natural product-drug interactions.","authors":"Victoria O Oyanna, John D Clarke","doi":"10.1080/03602532.2024.2386597","DOIUrl":"10.1080/03602532.2024.2386597","url":null,"abstract":"The growing co-consumption of botanical natural products with conventional medications has intensified the need to understand potential effects on drug safety and efficacy. This review delves into the intricacies of intestinal pharmacokinetic interactions between botanical natural products and drugs, such as alterations in drug solubility, permeability, transporter activity, and enzyme-mediated metabolism. It emphasizes the importance of understanding how drug solubility, dissolution, and osmolality interplay with botanical constituents in the gastrointestinal tract, potentially altering drug absorption and systemic exposure. Unlike reviews that focus primarily on enzyme and transporter mechanisms, this article highlights the lesser known but equally important mechanisms of interaction. Applying the Biopharmaceutics Drug Disposition Classification System (BDDCS) can serve as a framework for predicting and understanding these interactions. Through a comprehensive examination of specific botanical natural products such as byakkokaninjinto, green tea catechins, goldenseal, spinach extract, and quercetin, we illustrate the diversity of these interactions and their dependence on the physicochemical properties of the drug and the botanical constituents involved. This understanding is vital for healthcare professionals to effectively anticipate and manage potential natural product-drug interactions, ensuring optimal patient therapeutic outcomes. By exploring these emerging mechanisms, we aim to broaden the scope of natural product-drug interaction research and encourage comprehensive studies to better elucidate complex mechanisms.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"285-301"},"PeriodicalIF":3.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11606768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolism of new drug modalities research advances - 2023 year in review. 新药代谢研究进展 - 2023 年回顾。

IF 3.8 2区医学

Drug Metabolism Reviews Pub Date : 2024-08-01 Epub Date: 2024-07-05 DOI: 10.1080/03602532.2024.2370331

Bin Ma, Upendra A Argikar, Lionel Cheruzel, Sungjoon Cho, Simon Hauri, Kevin M Johnson, Joyce Liu, Simone Schadt, Shuai Wang, S Cyrus Khojasteh

引用次数: 0

Biotransformation Research Advances – 2023 year in review 生物转化研究进展 - 2023 年回顾

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2024-06-19 DOI: 10.1080/03602532.2024.2370330

S.Cyrus Khojasteh, UpendraA Argikar, Maria Chatzopoulou, Lionel Cheruzel, Sungjoon Cho, Deepika Dhaware, KevinM Johnson, AmitS Kalgutkar, Joyce Liu, Bin Ma, Hlaing Maw, JessicaA Rowley, HeranaKamal Seneviratne, Shuai Wang

引用次数: 0

The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure. CYP 和 UGT 药物代谢酶对大脑靶点药物暴露的潜在影响。

IF 3.8 2区医学

Drug Metabolism Reviews Pub Date : 2024-02-01 Epub Date: 2024-01-10 DOI: 10.1080/03602532.2023.2297154

Mengxu Zhang, Vivi Rottschäfer, Elizabeth C M de Lange

{"title":"The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure.","authors":"Mengxu Zhang, Vivi Rottschäfer, Elizabeth C M de Lange","doi":"10.1080/03602532.2023.2297154","DOIUrl":"10.1080/03602532.2023.2297154","url":null,"abstract":"Drug metabolism is one of the critical determinants of drug disposition throughout the body. While traditionally associated with the liver, recent research has unveiled the presence and functional significance of drug-metabolizing enzymes (DMEs) within the brain. Specifically, cytochrome P-450 enzymes (CYPs) and UDP-glucuronosyltransferases (UGTs) enzymes have emerged as key players in drug biotransformation within the central nervous system (CNS). This comprehensive review explores the cellular and subcellular distribution of CYPs and UGTs within the CNS, emphasizing regional expression and contrasting profiles between the liver and brain, humans and rats. Moreover, we discuss the impact of species and sex differences on CYPs and UGTs within the CNS. This review also provides an overview of methodologies for identifying and quantifying enzyme activities in the brain. Additionally, we present factors influencing CYPs and UGTs activities in the brain, including genetic polymorphisms, physiological variables, pathophysiological conditions, and environmental factors. Examples of CYP- and UGT-mediated drug metabolism within the brain are presented at the end, illustrating the pivotal role of these enzymes in drug therapy and potential toxicity. In conclusion, this review enhances our understanding of drug metabolism's significance in the brain, with a specific focus on CYPs and UGTs. Insights into the expression, activity, and influential factors of these enzymes within the CNS have crucial implications for drug development, the design of safe drug treatment strategies, and the comprehension of drug actions within the CNS. To that end, CNS pharmacokinetic (PK) models can be improved to further advance drug development and personalized therapy.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"1-30"},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138828752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review. 研究 CYP2J2 抑制剂与 QT 延长之间的关系：文献综述。

IF 3.8 2区医学

Drug Metabolism Reviews Pub Date : 2024-02-01 Epub Date: 2024-03-20 DOI: 10.1080/03602532.2024.2329928

Alexandra M Wiley, Jade Yang, Rivcka Madhani, Abhinav Nath, Rheem A Totah

{"title":"Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review.","authors":"Alexandra M Wiley, Jade Yang, Rivcka Madhani, Abhinav Nath, Rheem A Totah","doi":"10.1080/03602532.2024.2329928","DOIUrl":"10.1080/03602532.2024.2329928","url":null,"abstract":"Drug withdrawal post-marketing due to cardiotoxicity is a major concern for drug developers, regulatory agencies, and patients. One common mechanism of cardiotoxicity is through inhibition of cardiac ion channels, leading to prolongation of the QT interval and sometimes fatal arrythmias. Recently, oxylipin signaling compounds have been shown to bind to and alter ion channel function, and disruption in their cardiac levels may contribute to QT prolongation. Cytochrome P450 2J2 (CYP2J2) is the predominant CYP isoform expressed in cardiomyocytes, where it oxidizes arachidonic acid to cardioprotective epoxyeicosatrienoic acids (EETs). In addition to roles in vasodilation and angiogenesis, EETs bind to and activate various ion channels. CYP2J2 inhibition can lower EET levels and decrease their ability to preserve cardiac rhythm. In this review, we investigated the ability of known CYP inhibitors to cause QT prolongation using Certara's Drug Interaction Database. We discovered that among the multiple CYP isozymes, CYP2J2 inhibitors were more likely to also be QT-prolonging drugs (by approximately 2-fold). We explored potential binding interactions between these inhibitors and CYP2J2 using molecular docking and identified four amino acid residues (Phe61, Ala223, Asn231, and Leu402) predicted to interact with QT-prolonging drugs. The four residues are located near the opening of egress channel 2, highlighting the potential importance of this channel in CYP2J2 binding and inhibition. These findings suggest that if a drug inhibits CYP2J2 and interacts with one of these four residues, then it may have a higher risk of QT prolongation and more preclinical studies are warranted to assess cardiovascular safety.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"145-163"},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0